Reasons for switching ART: Comparison of data collected in 2012–2013 and 2014

Abstract

Persons living with HIV should remain on antiretroviral therapy (ART) indefinitely; however, a switch in the drug regimen is often necessary. In order to investigate if reasons for switching ART changed over time, we retrospectively analyzed reasons for switching and characteristics of switches among patients at Santa Maria Annunziata Hospital (OSMA), Florence area, Tuscany, Italy, over two periods (November 2012–October 2013 and November 2014–October 2015). The reasons for switching were classified as: simplification; virologic failure; occurrence of co-morbidities; and drug tolerability/toxicity issues. In period 1 (2012–2013), 18% patients changed their regimen vs. 13.5% in period 2 (2014–2015) (p = 0.019). Among reasons for switching, switches for simplification significantly increased from 41% in period 1 to 53% in period 2 (p = 0.004), with an increasing use of single tablet regimens (p = 0.002); no other statistically significant differences were found in other reasons for switching in periods 1 and 2. Characteristics of patients and of switches were analyzed and described. According to our data, the main reason for switching is now simplification, reflecting the recent changes in recommendations aimed to enhance adherence and quality of life, and to minimize, at the same time, drug toxicity and side effects.

Keywords

HIV/AIDS antiretroviral therapy reasons for switching

Get full access to this article

View all access options for this article.

References

Van den Eynde

and Podzamczer

Switch strategies in antiretroviral therapy regimens.

Expert Rev Anti Infect Ther 2014; 12: 1055–1074.

2. Utrillo

Vidal

Puig

et al.

Switching antiretroviral regimes for the treatment of HIV: safety implications.

Expert Opin Drug Saf 2016; 15: 1349–1360.

Antinori

Marcotullio

Andreoni

et al.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. New Microbiol 2016; 39: 93–109.

Di Biagio

Cozzi-Lepri

Prinapori

et al.

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort.

J Int AIDS Soc 2014; 17(4 Suppl 3): 19825.

Carrero-Gras

Antela

Muñoz-Rodríguez

et al.

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.

J Int AIDS Soc 2014; 17(4 Suppl 3): 19819.

Inzaule

Otieno

Kalyango

et al.

Incidence and predictors of first line antiretroviral regimen modification in western Kenya.

PLoS One 2014; 9: e93106.

Woldemedhin

and Wabe

NT.

The reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in Southern Ethiopia.

N Am J Med Sci 2012; 4: 19–23.

Sun

Liu

Shen

et al.

Reasons and risk factors for the initial regimen modification in Chinese treatment-naïve patients with HIV infection: a retrospective cohort analysis.

PLoS One 2015; 10: e0133242.

Reasons for switching ART: Comparison of data collected in 2012–2013 and 2014–2015 in Florence,Italy

Abstract

Keywords

Get full access to this article

References